Results from the first part of a Phase I/II trial (NCT06569823) showed that Z-1018 generated immune responses comparable to ...

Viking Therapeutics’ VK2735 achieves a 10.9% placebo-adjusted weight loss at 13 weeks, but a less than ideal safety profile ...

Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy ...

Due to a lack of resources and personnel, the FDA has delayed until October its decision on lifting a clinical hold on ALS ...

AbbVie Inc. (NYSE:ABBV) on Thursday released topline results from the second of two pivotal studies of the Phase 3 UP-AA clinical program evaluating the safety and efficacy of upadacitinib (RINVOQ; 15 ...

Research reveals innovative methods for detecting minimal residual disease in ovarian cancer, enhancing prognosis and paving ...

A clinical trial of an experimental cell therapy shows promising results for glioblastoma patients, with tumors disappearing ...

Cohesys Inc., a Toronto-based medical device developer of resorbable fixation technologies, today announced that the first ...

Premier Health’s Miami Valley Hospital South is the first of 23 international sites to open enrollment for a new clinical trial focused on advanced ovarian and related cancer.

"Investigational drug for people with treatment-resistant epilepsy." ScienceDaily. ScienceDaily, 21 November 2019. <www.sciencedaily.com / releases / 2019 / 11 / 191121090947.htm>.